Loading clinical trials...

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients | Clinical Trials | Clareo Health

COMPLETEDPhase 4NCT04080648

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

Biologic such as guselkumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described according t...

Lead sponsor: University Hospital, Ghent•7 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 4

Proactive TDM Versus Standard Use of Biologics in Psoriasis

NCT06398106 · Psoriasis Vulgaris

RECRUITINGNA

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NCT04080635 · Psoriasis Vulgaris

COMPLETEDPhase 4

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

NCT04340076 · Psoriasis, Psoriasis Vulgaris

WITHDRAWNNA

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

NCT03507946 · Psoriasis Vulgaris

COMPLETEDPhase 1

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

NCT06191042 · Psoriasis Vulgaris, Psoriatic Arthritis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 19, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment79

Start dateJun 2018

Last updatedSep 19, 2024

Condition

Psoriasis Vulgaris

Locations shown

AZ Maria Middelares

Ghent, East-Flanders

AZ Sint-Lucas

Ghent, East-Flanders

University Hospital Ghent

Ghent, East-Flanders

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Proactive TDM Versus Standard Use of Biologics in Psoriasis

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris

A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis

Trial snapshot

Condition

Locations shown

For caregivers